Regeneron Pharmaceuticals Stock News

Related Stocks: AEO , REGN , WHLRD.PFD , WHLRP.PFD , PYPL , SONO , TPB , MHO , RLGY , MA ,

Intellia (NTLA) partners with ONK Therapeutics. The collaboration utilises their respective proprietary platforms to develop allogeneic CRISPR-based NK cell therapies for the treatment of cancer.

Which ETFs Should Investors Be Watching Now? Our Favorite Is The IBB

Gilead's (GILD) Veklury (remdesivir) retains antiviral activity against Omicron, Delta and other emergent SARS-CoV-2 variants in multiple in vitro studies.

Lilly's (LLY) new antibody-drug, bebtelovimab is authorized to treat certain non-hospitalized adults and pediatric patients with mild-to-moderate COVID-19 who are at high risk of progressing to severe

Bebtelovimab wins emergency use authorization for Covid-19 Related Stocks: LLY , REGN , ABCL ,

Merck is 90% focused on human drugs and is highly diversified globally. See why I think MRK stock could deliver 24% annual returns over the next two years.

Regeneron <> has recorded the biggest intraday gain in more than three months after reporting 44-week data from a Phase 2 trial for the company’s blockbuster therapy…

Someone with a lot of money to spend has taken a bearish stance on Regeneron Pharmaceuticals (NASDAQ: REGN ). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga. Whether this is an institution or just a wealthy individual, we don''t know. But when something this big happens with REGN, it often means somebody knows something is about to happen. So how do we know what this whale just did? Today, Benzinga ''s options scanner spotted 24 uncommon options trades for Regeneron Pharmaceuticals. This isn''t normal. The overall sentiment of these big-money traders is split between 45% bullish and 54%, bearish. Out of all of the special options we uncovered, 10 are puts, for a total amount of $504,776, and 14 are calls, for a total amount of $810,794. What''s The Price Target? Taking into account the Volume and Open Interest on these contracts, it appears that whales have … Full story available on Benzinga.

Alnylam's (ALNY) earnings fall shy of estimates in the fourth quarter of 2021 while revenues beat the same. The company issues 2022 guidance for net product revenues.

Ultragenyx (RARE) reports wider-than-expected loss in the fourth quarter of 2021 while revenues miss estimates.

Our Motley Fool roundtable likes Intercept Pharma, Viking Therapeutics, and Vir Bio.

Alnylam Pharmaceuticals Inc''s (NASDAQ: ALNY ) Q4 product revenues increased 76% Y/Y to $198.5 million , primarily due to the continued global expansion of Onpattro and Givlaari, and sales from a third commercial product, Oxlumo. Collaborations sales increased 18%, primarily due to increased revenue from collaboration agreements with Regeneron Pharmaceuticals Inc (NASDAQ: REGN ) and Novartis AG (NYSE: Full story available on Benzinga.com

Vir (VIR), Glaxo's sotrovimab retains neutralizing activity against the BA.2 subvariant of Omicron, per preclinical data.

Regeneron (REGN) and Sanofi get Priority Review for their sBLA in the United States seeking label expansion of Dupixent.